Volume 5 Supplement 1

The 4th Recombinant Protein Production Meeting: a comparative view on host physiology

Open Access

Production of human α1 proteinase inhibitor from Aspergillus niger

  • Liat Chill1,
  • Loc B Trinh1,
  • Elena Karnaukhova2,
  • Yakir Ophir2,
  • Basil Golding2 and
  • Joseph Shiloach1
Microbial Cell Factories20065(Suppl 1):P62

https://doi.org/10.1186/1475-2859-5-S1-P62

Published: 10 October 2006

Background

α1 proteinase inhibitor (α1PI) belongs to the serin protease inhibitor (serpin) family; it is responsible for 90% of the trypsin inhibitory capacity of human plasma. Its primary physiological role is to inhibit neutrophil elastase that degrades elastin, collagen and proteoglycan and can cause extensive lung damage. α1PI deficiency can result in lung emphisema in adults, liver disease in children and is also associated with cystic fibrosis, arthritis and other malignant conditions [13]. Human plasma-derived α1PI is a licensed product used for replacement therapy. Although viral inactivation measures are taken, products derived from human plasma carry the risk of contamination with blood-borne pathogens, and therefore recombinant is an attractive alternative.

α1PI exhibits a molecular mass of approximately 52 kD, has 394 amino acids, a single cystein residue and three carbohydrate attachment sites at asparagine residues 46, 83 and 247 [4, 5]. Significant research effort was directed to produce recombinant human α1PI in E. coli [6], yeast [7], transgenic mice and sheep as well as plant cells [3]. E-coli produced an unglycosylated product, the yeast produced incorrect glycosylation and the transgenic animals pose the same threats as plasma derived product.

Results

Human α1PI was cloned and expressed in Aspergillus niger, filamentous fungus that can grow in defined media and had the ability to perform glycosylation. Submerged culture conditions were established: using starch as carbon source, 30% dissolved oxygen concentration, pH 7.0 and 28°C; 10 mg per liter of active α1PI were secreted to the growth media in 40 hours. Controlling the protein proteolysis was found to be an important factor in the production from the fungus. The effect of carbon sources and growth conditions on the production and stability of the protein will be presented and evaluated.

Authors’ Affiliations

(1)
Biotechnology Unit, NIDDK, NIH
(2)
Division of Hematology, CBER, FDA

References

  1. Mattes E, Matthiessen HP, Turecek PL, Schwarz HP: Preparation and properties of an alpha-1-protease inhibitor concentrate with high specific activity. Vox Sang. 2001, 81: 29-36. 10.1046/j.1423-0410.2001.00049.x.View ArticleGoogle Scholar
  2. Travis J, Owen M, George P, Carrell R, Rosenberg S, Hallewell RA, Barr PJ: Isolation and properties of recombinant DNA produced variants of Human α1-proteinase inhibitor. J Biol Chem. 1985, 260: 4384-4389.Google Scholar
  3. Huang J, Sutliff TD, Wu L, Nandi S, Benge K, Terashima M, Ralston AH, Drohan W, Huang N, Rodriguez RL: Expression and purification of functional human α-1-antitrypsin from cultured plant cells. Biotechnol Prog. 2001, 17: 126-133. 10.1021/bp0001516.View ArticleGoogle Scholar
  4. Chen SX, Hammond DJ, Klos AM, Wood WD, Wydick JE, Lebing WR: Chromatographic purification of human α1 proteinase inhibitor from dissolved Cohn fraction IV-1 paste. J Chromatogr A. 1998, 800: 207-218. 10.1016/S0021-9673(97)01119-9.View ArticleGoogle Scholar
  5. Carrell RW, Jeppsson JO, Laurell CB, Brennan SO, Owen MC, Vaughan L, Boswell R: Structure and variation of human α1-antytrypsin. Nature. 298: 329-334.View ArticleGoogle Scholar
  6. Courtney M, Buchwalder A, Tessier L, Jaye M, Benavente A, Balland A, Kohli V, Lathe R, Tolstoshev P, Lecocq J: High level production of biologically acyive α-1-antitrypsin in Escherichia coli. Proc Natl Acad Sci USA. 1984, 81: 669-673. 10.1073/pnas.81.3.669.View ArticleGoogle Scholar
  7. Kwon KS, Song M, Yu MH: Purification and characterization of a1-antitrypsin secreted by recombinant yeast Saccharomyces diastaticus. J Biotechnol. 1995, 42: 19-10.1016/0168-1656(95)00079-6. 10.1016/0168-1656(95)00079-6.View ArticleGoogle Scholar

Copyright

© Chill et al; licensee BioMed Central Ltd. 2006

This article is published under license to BioMed Central Ltd.

Advertisement